Objective: To investigate the effect of hemoglobin (Hb) on the efficacy of chimeric antigen receptor T cell therapy (CAR-T) in patients with multiple myeloma (MM).
Methods: From June 2017 to December 2020, 76 MM patients who received CAR-T therapy in the Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, with complete clinical data and evaluable efficacy, were selected as the research objects. According to the receiver operating characteristic (ROC) curve, the best cut-off value was obtained. The patients were divided into groups on the basis of Hb 105.5 g/L as the cut-off value. The age, sex, serum calcium, β2-microglobulin, serum creatinine, lactate dehydrogenase (LDH), and the influencing factors of CAR-T treatment efficacy in MM patients were analyzed.
Results: Hb was an influencing factor of efficacy. Univariate analysis showed that Hb, LDH, and albumin affected the efficacy of CAR-T therapy. Multivariate analysis showed that Hb ( OR=1.039, 95% CI: 1.002-1.078) and LDH ( OR=1.014, 95% CI: 1.000-1.027) were the influencing factors for the efficacy of CAR-T therapy.
Conclusion: The efficacy of CAR-T therapy in MM patients with low Hb is poor, and Hb is a factor affecting the efficacy of CAR-T therapy.
题目: 血红蛋白对多发性骨髓瘤患者CAR-T治疗疗效的影响.
目的: 探讨血红蛋白（Hb）对多发性骨髓瘤患者CAR-T治疗疗效的影响。.
方法: 选取2017年6月至2020年12月于徐州医科大学附属医院血液科接受CAR-T免疫治疗且可评估疗效的76例多发性骨髓瘤患者为研究对象。根据受试者工作特征曲线得出最佳截断值，Hb以105.5 g/L为界值对患者进行分组，分析各组患者年龄、性别、血清钙、β2-微球蛋白、血肌酐、乳酸脱氢酶等的差异，以及CAR-T治疗疗效的影响因素。.
结果: Hb是疗效的影响因素；单因素分析结果显示，Hb、乳酸脱氢酶、白蛋白影响患者CAR-T治疗的疗效；多因素分析显示，Hb（ OR=1.039，95%CI：1.002-1.078）、乳酸脱氢酶（ OR=1.014，95% CI：1.000-1.027）是患者CAR-T治疗疗效的影响因素。.
结论: 低Hb患者接受CAR-T治疗的疗效差，Hb是影响多发性骨髓瘤患者CAR-T治疗疗效的因素。.
Keywords: chimeric antigen receptor T cell therapy; efficacy; hemoglobin; multiple myeloma.